With 0.49 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.57 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.06 whereas the lowest price it dropped to was $6.63. The 52-week range on LIMN shows that it touched its highest point at $33.66 and its lowest point at $4.40 during that stretch. Beta for the stock currently stands at 0.51.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LIMN was up-trending over the past week, with a rise of 15.74%, but this was down by -29.43% over a month. Three-month performance surged to 25.05% while six-month performance fell -39.35%. The stock lost -40.37% in the past year, while it has lost -35.61% so far this year.
Float and Shares Shorts:
At present, 26.01 million LIMN shares are outstanding with a float of 11.41 million shares on hand for trading. On 2025-07-15, short shares totaled 0.17 million, which was 77.99999999999999 higher than short shares on 1749772800.
Institutional Ownership:
Through their ownership of 0.00282 of LIMN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, LIMN reported revenue of $0.0 and operating income of -$255.0. The EBITDA in the recently reported quarter was -$255.0 and diluted EPS was -$1e-05.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
